Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TMB

- PMLiVE

BMS gains FDA approval for second Opdivo combo in kidney cancer

BMS' Opdivo/Yervoy regimen was its first combo to be approved for advanced renal cell carcinoma

- PMLiVE

BMS aims for US approval of Opdivo combo in stomach cancer

US regulator has set a goal date for a decision on 25 May

- PMLiVE

BMS’ Opdivo wins EU approval for second-line oesophageal cancer

Competition heats up with rival checkpoint inhibitor Keytruda

- PMLiVE

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC

Checkpoint inhibitor plus chemo meets first primary endpoint in late-stage trial

- PMLiVE

BMS eyes approval for second Opdivo combo in kidney cancer

Detailed results presented at ESMO 2020 virtual congress

- PMLiVE

Keytruda improves survival in first-line oesophageal cancer

Topline data demonstrates promising efficacy in the first-line setting

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

BMS scores first oesophageal cancer nod for Opdivo in Japan

Approval in Japan comes before US okay

- PMLiVE

BMS’ Opdivo combo misses the mark in pancreatic cancer

Failed to reach primary endpoint of progression-free survial

- PMLiVE

BMS unveils long-term results for Opdivo in kidney cancer

Results include updated data for Opdivo with or without Yervoy

- PMLiVE

Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

BMS share price up by 3% on the back of results

Bristol Myers Squibb logo

Another blow for BMS in first-line NSCLC as it pulls EU filing

Opdivo/Yervoy combination is still under review with the FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links